Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2023

Open Access 01-12-2023 | Study protocol

Comparison of different weight-based scalars of remimazolam tosylate for anesthesia induction in obese patients: study protocol for a prospective, controlled trial

Authors: Wenwen Ni, Xiuwen Yi, Lili Feng, Yilei Shen, Jiali Jiao, Yirong Cai, Danyun Fu, Yuan Han, Ji’e Jia, Wenxian Li

Published in: Trials | Issue 1/2023

Login to get access

Abstract

Background

The physiologic and anthropometric characteristics changes associated with obesity may result in the alternation of pharmacologic management. Remimazolam tosylate is a new type of ultra-short-acting benzodiazepine with stable context-sensitive half-time (CSHT) and no lipid accumulation after long-time infusion. Although remimazolam tosylate has potential advantages for the induction and maintenance of anesthesia in obese patients, the appropriate induction dosing scalars among obese patients are unknown. Therefore, we aim to compare the different weight-based scalars for dosing remimazolam tosylate of anesthesia induction among obese patients.

Methods/design

The study will be performed as a prospective, single-center, double-blind, controlled clinical trial. The study design is a comparison of remimazolam tosylate requirements based on total body weight (TBW) or lean body weight (LBW) to reach a Modified Observer’s Assessment of Alertness and Sedation (MOAA/S) score of 0 among obese subjects (BMI ≥ 35 kg/m2). Another twenty normal-weight subjects (18.5 kg/m2 ≤ BMI < 25 kg/m2) will be enrolled as a control group, whose induction dose is scaled based on TBW. The infusion rate of remimazolam tosylate during induction is 12 mg/kg/h in all groups.

Discussion

Results of the present study will provide evidence of dose scalar of remimazolam tosylate to guide the clinical practice of anesthesia induction in obese patients.

Trial registration

Chinese Clinical Trial Registry ChiCTR220005664. Registered on 9 February 2022, https://​www.​chictr.​org.​cn/​showproj.​aspx?​proj=​151150.
Literature
1.
Afshin A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.CrossRefPubMed
2.
Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010;105(Suppl 1):i16-23.CrossRefPubMed
3.
Imber DA, et al. Respiratory management of perioperative obese patients. Respir Care. 2016;61(12):1681–92.CrossRefPubMed
4.
Kilpatrick GJ, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107(1):60–6.CrossRefPubMed
5.
Rudolph U, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401(6755):796–800.CrossRefPubMed
6.
McKernan RM, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000;3(6):587–92.CrossRefPubMed
7.
Worthington MT, et al. A phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117(5):1093–100.CrossRefPubMed
8.
Schüttler J, et al. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology. 2020;132(4):636–51.CrossRefPubMed
9.
Johnson KB. New horizons in sedative hypnotic drug development: fast, clean, and soft. Anesth Analg. 2012;115(2):220–2.CrossRefPubMed
10.
Wiltshire HR, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012;115(2):284–96.CrossRefPubMed
11.
Yoshida A, et al. Anesthetic management for the sleep-awake-sleep technique of awake craniotomy using a novel benzodiazepine remimazolam and its antagonist flumazenil. JA Clin Rep. 2021;7(1):14.CrossRefPubMedPubMedCentral
12.
Brohan J, Goudra BG. The role of GABA receptor agonists in anesthesia and sedation. CNS Drugs. 2017;31(10):845–56.CrossRefPubMed
13.
14.
Berezhkovskiy LM. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects. J Pharm Sci. 2011;100(6):2482–97.CrossRefPubMed
15.
Jain R, et al. Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther. 2011;90(1):77–89.CrossRefPubMed
16.
Collis T, et al. Relations of stroke volume and cardiac output to body composition: the strong heart study. Circulation. 2001;103(6):820–5.CrossRefPubMed
17.
18.
19.
Griggs JJ, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553–61.CrossRefPubMed
20.
Sharma S, Arora L. Anesthesia for the morbidly obese patient. Anesthesiol Clin. 2020;38(1):197–212.CrossRefPubMed
21.
Janmahasatian S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051–65.CrossRefPubMed
22.
Chernik DA, et al. Validity and reliability of the Observer’s Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990;10(4):244–51.PubMed
23.
Doi M, et al. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020;34(4):543–53.CrossRefPubMed
24.
Shibutani K, et al. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. Br J Anaesth. 2005;95(3):377–83.CrossRefPubMed
25.
Leykin Y, et al. The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg. 2004;99(4):1086–9.CrossRefPubMed
26.
Ingrande J, Brodsky JB, Lemmens HJ. Lean body weight scalar for the anesthetic induction dose of propofol in morbidly obese subjects. Anesth Analg. 2011;113(1):57–62.CrossRefPubMed
27.
Doi M, et al. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth. 2020;34(4):491–501.CrossRefPubMed
28.
Baraka AS, et al. Supplementation of pre-oxygenation in morbidly obese patients using nasopharyngeal oxygen insufflation. Anaesthesia. 2007;62(8):769–73.CrossRefPubMed
29.
Subramani Y, et al. Optimal propofol induction dose in morbidly obese patients: a randomized controlled trial comparing the bispectral index and lean body weight scalar. Can J Anaesth. 2017;64(5):471–9.CrossRefPubMed
30.
Schneider JH, et al. Transient lower esophageal sphincter relaxation in morbid obesity. Obes Surg. 2009;19(5):595–600.CrossRefPubMed
Metadata
Title
Comparison of different weight-based scalars of remimazolam tosylate for anesthesia induction in obese patients: study protocol for a prospective, controlled trial
Authors
Wenwen Ni
Xiuwen Yi
Lili Feng
Yilei Shen
Jiali Jiao
Yirong Cai
Danyun Fu
Yuan Han
Ji’e Jia
Wenxian Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Trials / Issue 1/2023
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-023-07739-6

Other articles of this Issue 1/2023

Trials 1/2023 Go to the issue

Study protocol

BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa—a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings

Letter

A response to Al et al. Trials 2023;24:233

Study protocol

A protocol for a single center, randomized, controlled trial comparing the clinical efficacy of 3% diquafosol and 0.1% hyaluronic acid in diabetic patients with dry eye disease

Study protocol

SuRxgWell: study protocol for a randomized controlled trial of telemedicine-based digital cognitive behavioral intervention for high anxiety and depression among patients undergoing elective hip and knee arthroplasty surgery

Methodology

Creating a best practice template for participant communication plans in global health clinical studies

Study protocol

Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial